Neurofeedback-Based Digital Therapeutics for the Diagnosis and Treatment of ADHD in Children.
Key facts
- Who runs it
- Lei Lei, MD
- Where
- China2 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 210 people, planned
- Started
- 24 Feb 2023
- Planned end
- 31 Dec 2025
- Type of study
- Interventional, 3 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Concerta
- Digital therapeutics
- Record updated
- 10 June 2025
Who can take part
- Age
- 6 years to 12 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Meet the diagnostic criteria established by the 5th edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) for ADHD
- Digital Cancellation Test total score<50 points
- Raven's Standard Progressive Matrices score≥85
- 6 years ≤ Age<12 years
- No interventions for ADHD received within 4 weeks
- No color blindness
Who cannot take part
- Patients with organic mental disorders, schizophrenia, bipolar disorder, depressive disorders, and other psychiatric conditions
- Patients with comorbid autism spectrum disorder, Tourette's syndrome, and other neurodevelopmental disorders
- Patients with comorbid conduct disorders
- Patients with severe traumatic brain injury or neurological disorders
- Patients with a history of severe somatic diseases
- Patients with a history of substance or drug dependency
The main criteria, as questions
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 6 and 12 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
A multi-center, randomized controlled trial is being conducted to investigate the efficacy of a novel digital therapeutics (DTx) program that utilizes a cross-training approach between neurofeedback training and executive function training for pediatric patients (aged 6-12) diagnosed with ADHD. This gamified interactive program is designed to improve attention deficits and executive function impairments in pediatric patients with ADHD. It is delivered through an engaging iPad game in a home-based treatment format. Patients will be randomly assigned to one of three groups: medication alone, digital therapeutics alone, or a combination of both interventions. Subjects will undergo 30 treatment sessions over the 8-week period, with each session lasting 30 minutes. Investigators will reassess symptoms of ADHD, executive functions, and objective measures of attention at the end of the treatment. Additionally, questionnaires will be distributed to parents to gather their insights and feedback on the treatment approach. This innovative digital therapeutics approach is expected to improve ADHD symptoms individually and enhance therapeutic outcomes when used alongside conventional drug treatment regimens.
The 3 groups in the trial
- Medication groupExisting treatment, for comparison
The medication group will take Methylphenidate Hydrochloride Extended-Release Tablets with a fixed dose for eight weeks.
Treatment: Concerta
- Digital therapeutics groupTreatment being tested
The digital therapeutics group will complete 30 training sessions within 8 weeks.
Treatment: Digital therapeutics
- Combination groupTreatment being tested
The combination group will take Methylphenidate Hydrochloride Extended-Release Tablets while undergoing digital therapeutics.
Treatment: Concerta and Digital therapeutics
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Neurofeedback-Based Digital Therapeutics for the Diagnosis and Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Children.
- Criteria questions
- Built from NCT06369714, who can take part
- Publications
- Record updated
- 10 June 2025